• Proceedings of the Korean Society of Applied Pharmacology
• /
• 1993.04a
• /
• pp.93-93
• /
• 1993

도파민 D 수용체 및 5-HT 수용체 차단기전을 지닌 새로운 항정신분열증 약물인 risperidone은 활성형 대사물로 9-OH risperidone을 체내에서 생성하는 바, 이 대사과정의 유전적 다형성의 여부 즉 hydroxylation 과정에 CYPIID6의 관여 여부를 검토코자 하였다. Metoprolol 100 mg 경구투여로 CYPIID6의 대사능의 표현형을 결정한 12명의 정상 피험자(11명: extensive metabolizer, 1명: poor metabolizer)를 대상으로 하였으며, 피험자는 risperidone 1 또는 2 mg 경구투여후 혈중 risperidone 및 9-OH risperidone 농도를 경시적으로 radioimmunoassay법으로 측정하였다. 이들 피험자중 6명의 extensive metabolizer는 quinidine 600 mg/day의 용량 투여로 CYPIID6의 활성도를 완전 억제시킨 후 risperidone 1 mg 경구투여에 따른 약동학적 성상을 재검토하여 risperidone hydroxylation에 CYPIID6의 관여 여부를 검토하였다. 1) 1명의 poor metabolizer는 extensive metabolizer에 비해 현저히 긴 risperidone 반감기를 보였다. 2) 12명의 피험자에서 관찰된 metoprolol metabolic ratio는 risperidone 혈장 반감기 및 log(risperidone AUC/9-OH-risperidone AUC)와 유의한 상관성을 나타내었다. 3) Quinidine 투여는 risperidone의 반감기의 유의한 증가와 9OH risperidone AUC의 현저한 감소를 보였으나, 9-hydroxylation 대사과정이 완전히 억제되지는 않았다.

• Journal of the Korean Academy of Child and Adolescent Psychiatry
• /
• v.13 no.1
• /
• pp.129-138
• /
• 2002

Objectives：In order to treatment guideline of ADHD, present clinical practise of child psychiatrists and their opinion of optimal intervention were evaluated. Methods：Structured questionnaire items about diagnostic workup, drug choice of 5 different situations according to different co-morbid disorders, and non - pharmacological treatment were applied to 32 child psychiatrists working at university and general hospital. we compared the data with Texas Algorithm Project guideline. Results：(1) Intelligence Test, Sentence Completion Test, sustained attention test, and Conner's questionnaire were the basic routine test that must be performed. (2) Main trend of medication in this study was not different from TAP guideline. (3) In case of co-morbid tic disorder, first recommending drug is still psychostimulant in the TAP guideline. But in this study initial psychostimulant prescription was not main trend. (4) In case of MPH non-response co-morbid disruptive behavior disorder, MPH medication combined with other drug were more common than switching to other drug as suggested the TAP guidelines. (5) In non-pharmacological treatment, most child psychiatrists reported the importance of parent management. Conclusion：There were some difference in medication trend in this study compared with TAP guideline. Further study and conference are needed for experts consensus in Korea.

• Korean Journal of Schizophrenia Research
• /
• v.22 no.2
• /
• pp.21-33
• /
• 2019

Objectives: The current study covers a secondary revision of the guidelines for the pharmacotherapy of schizophrenia issued by the Korean Medication Algorithm for Schizophrenia (KMAP-SCZ) 2001, specifically for co-existing symptoms and antipsychotics-related side-effects in schizophrenia patients. Methods: An expert consensus regarding the strategies of pharmacotherapy for positive symptoms of schizophrenia, co-existing symptoms of schizophrenia, and side-effect of antipsychotics in patients with schizophrenia was retrieved by responses obtained using a 30-item questionnaire. Results: For the co-existing symptoms, agitation could be treated with oral or intramuscular injection of benzodiazepine or antipsychotics; depressive symptoms with atypical antipsychotics and adjunctive use of antidepressant; obsessive-compulsive symptoms with selective serotonin reuptake inhibitors and antipsychotics other than clozapine and olanzapine; negative symptoms with atypical antipsychotics or antidepressants; higher risk of suicide with clozapine; comorbid substance abuse with use of naltrexone or bupropion/varenicline, respectively. For the antipsychotics-related side effects, anticholinergics (extrapyramidal symptom), propranolol and benzodiazepine (akathisia), topiramate or metformin (weight gain), change of antipsychotics to aripiprazole (hyperprolactinemia and prolonged QTc) or clozapine (tardive dyskinesia) could be used. Conclusion: Updated pharmacotherapy strategies for co-existing symptoms and antipsychotics-related side effects in schizophrenia patients as presented in KMAP-SCZ 2019 could help effective clinical decision making of psychiatrists as a preferable option.

• Korean Journal of Biological Psychiatry
• /
• v.23 no.3
• /
• pp.116-121
• /
• 2016

Objectives Experience of early childhood abuse elevates the risk of developing schizophrenia in later period of life, incidence of psychiatric comorbidity, symptomatic severity and complexity. In this context, we hypothesized that the pattern of psychotropic medication used would reflect this; those with childhood trauma will received more types and higher doses of psychotropic medication. Methods From our database of 102 outpatients diagnosed with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) schizophrenia, we analyzed experiences of childhood trauma measured by the Childhood Trauma Questionnaire-Short Form and types and dose of prescribed psychotropic medication. Results We found significant positive correlations between child sexual abuse and the number of psychotropic medications (p = 0.029) and between child emotional neglect and the number of psychotropic medications other than antipsychotics (p = 0.045). Conclusions This preliminary study suggests that the pattern of psychotropic use may be affected by types of childhood trauma. Further studies will have to shed light on mediating factors such as symptoms or comorbid conditions that lead to prescription of certain psychotropic class.

• Korean Journal of Psychosomatic Medicine
• /
• v.15 no.2
• /
• pp.65-72
• /
• 2007

Fatigue is a significant problem in health care. The relationship between chronic fatigue and psychiatric disorders has generated significant interest in recent years. Increased rates of psychiatric disorder among individuals with chronic fatigue have been reported. Fatigue may be defined as physical and/or mental weariness resulting from exertion. The cause of fatigue is complex, influenced by events occurring in both the periphery and the central nervous system. Because fatigue may result from a number of causes, it should be treated comprehensively. The treatment is largely symptomatic and rehabilitative.

• Korean Journal of Biological Psychiatry
• /
• v.30 no.1
• /
• pp.1-6
• /
• 2023

Many psychiatric disorders are associated with brain functional dysfunctions and neuronal degeneration. According to the research so far, enhanced brain plasticity reduces neurodegeneration and recovers neuronal damage. Brain-derived neurotrophic factor (BDNF) is one of the most extensively studied neurotrophins in the mammalian brain that plays major roles in neuronal survival, development, growth, and maintenance of neurons in brain circuits related to emotion and cognitive function. Also, BDNF plays an important role in brain plasticity, influencing dendritic spines in the hippocampus neurogenesis. Changes in neurogenesis and dendritic density can improve psychiatric symptoms and cognitive functions. BDNF has potent effects on brain plasticity through biochemical mechanisms, cellular signal pathways, and epigenetic changes. There are pharmacological and non-pharmacological interventions to increase the expression of BDNF and enhance brain plasticity. Non-pharmacological interventions such as physical exercise, nutritional change, environmental enrichment, and neuromodulation have biological mechanisms that increase the expression of BDNF and brain plasticity. Non-pharmacological interventions are cost-effective and safe ways to improve psychiatric symptoms.

• Proceedings of the Korean Society of Applied Pharmacology
• /
• 1992.05a
• /
• pp.56-56
• /
• 1992

Risperidone은 D$_2$-수용체와 HT$_2$-수용체 차단효과를 동시에 지녀, 차세대 항정신분열증 치료제로의 가능성을 보이고 있는 약물이다. 그러나 risperidone의 주대사가 CYPIID1에 의할 가능성이 시사되고 있다. 본 연구에서는 향후 항정신병 치료제의 임상 제 1상 연구의 적정 모형 검토를 위해 risperidone율 모델 약물로 체내 약물의 동태, 내약성 및 약물 유전학적 특성등을 검토하였다. CYPIID1의 대사능을 검정한 12명의 정상 성인(11명: extensive metabolizer, 1명: poor metabolizer)을 대상으로 risperidone 투여 시험(placebo, 1, 2 mg)을 무작위 단일맹검 교차시험으로 시행하였다. 투약후 72시간까지 경시적으로 혈액, 뇨 채취 및 ECG lead II, 혈압/맥박의 변동 등을 측정하고, visual analog scale에 의해 중추신경계 주관적 증상들을 관찰 하였다. 혈장 risperidone 및 그 활성형대사물 9-OH risperidone 및 prolactin 농도는 radioimmunoassay법으로 측정하였다.

• 한국사회복지학회:학술대회논문집
• /
• 2004.04a
• /
• pp.673-703
• /
• 2004

• 대한임상약리학회:학술대회논문집
• /
• 2003.06a
• /
• pp.19-19
• /
• 2003

• Clinical Psychopharmacology and Neuroscience
• /
• v.16 no.4
• /
• pp.508-508
• /
• 2018